Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Burrill & CO (Life Sciences GP), LLC
 2. Date of Event Requiring Statement (Month/Day/Year)
04/26/2007		 3. Issuer Name and Ticker or Trading Symbol
Pharmasset Inc [VRUS]
(Last)
(First)
(Middle)
ONE EMBARCADERO CENTER, SUITE 2700, 		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
04/26/2007
(Street)

SAN FRANCISCO, CA 94111		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series D-1 Warrants (1)   (2) 08/04/2009 Common Stock 212,099 (3) $ 0.15 I See Footnotes (3) (4)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Burrill & CO (Life Sciences GP), LLC
ONE EMBARCADERO CENTER, SUITE 2700
SAN FRANCISCO, CA 94111		     X    
BURRILL LIFE SCIENCES CAPITAL FUND LP
ONE EMBARCADERO CENTER
SUITE 2700
SAN FRANCISCO, CA 94111		     X    
Burrill & CO (Indiana GP), LLC
ONE EMBARCADERO CENTER
SUITE 2700
SAN FRANCISCO, CA 94111		     X    
Burrill Indiana Life Sciences Capital Fund, L.P.
ONE EMBARCADERO CENTER
SUITE 2700
SAN FRANCISCO, CA 94111		     X    

Signatures

/s/ G. Steven Burrill, Managing Member, on behalf of Burrill & Company (Life Sciences GP), LLC 05/04/2007
**Signature of Reporting Person Date
/s/ G. Steven Burrill, Managing Member of Burrill & Company (Life Sciences GP), LLC, its sole general partner 05/04/2007
**Signature of Reporting Person Date
/s/ G. Steven Burrill, Managing Member 05/04/2007
**Signature of Reporting Person Date
/s/ G. Steven Burrill, Managing Member of Burrill & Company (Indiana GP), LLC, its sole general partner 05/04/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 is being filed as an amendment to the Form 3 filed on April 26, 2007 to correct the information regarding the Series D-1 Warrants held by the reporting persons. The exercise price has been changed from $0.10 to $0.15, and the number of warrants held by each fund has been changed from 176,477 to 173,536, and from 39,217 to 38,563, respectively.
(2) There will be an automatic cashless net exercise of the Series D-1 Warrants into shares of Pharmasset common stock upon the closing of their initial public offering.
(3) Consists of warrants to acquire 173,536 shares held by Burrill Life Sciences Capital Fund, L.P. and 38,563 shares held by Burrill Indiana Life Sciences Capital Fund, L.P., after giving effect to a 1 for 1.5 reverse stock split that became effective on April 19, 2007, and a reduction in the number of shares received pursuant to the election of a cashless exercise feature.
(4) The sole general partner of Burrill Life Sciences Capital Fund, L.P. is Burrill & Company (Life Sciences GP), LLC, and the sole general partner of Burrill Indiana Life Sciences Capital Fund, L.P. is Burrill & Company (Indiana GP), LLC. Burrill & Company (Life Sciences GP), LLC and Burrill & Company (Indiana GP), LLC are indirect beneficial owners of these securities and each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.